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ABSTRACT
Background. The Dapagliflozin and Prevention of Adverse
outcomes in Chronic Kidney Disease (DAPA-CKD;
NCT03036150) trial was designed to assess the effect of the so-
dium–glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin
on kidney and cardiovascular events in participants with CKD
with and without type 2 diabetes (T2D). This analysis reports
the baseline characteristics of those recruited, comparing them
with those enrolled in other trials.
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Methods. In DAPA-CKD, 4304 participants with a urinary
albumin:creatinine ratio (UACR) 200mg/g and estimated
glomerular filtration rate (eGFR) between 25 and 75mL/min/
1.73m2 were randomized to dapagliflozin 10mg once daily or
placebo. Mean eGFR was 43.1mL/min/1.73m2 and median
UACRwas 949mg/g (108mg/mmol).
Results. Overall, 2906 participants (68%) had a diagnosis of
T2D and of these, 396 had CKD ascribed to a cause other than
diabetes. The most common causes of CKD after diabetes
(n¼ 2510) were ischaemic/hypertensive nephropathy (n¼ 687)
and chronic glomerulonephritis (n¼ 695), of which immuno-
globulin A nephropathy (n¼ 270) was the most common. A to-
tal of 4174 participants (97%) were receiving an angiotensin-
converting enzyme inhibitor or angiotensin receptor blocker,
1882 (43.7%) diuretics, 229 (5.3%) mineralocorticoid receptor
antagonists and 122 (2.8%) glucagon-like peptide 1 receptor
agonists. In contrast to the Canagliflozin and Renal Events in
Diabetes with Established Nephropathy Clinical Evaluation
(CREDENCE), the DAPA-CKD trial enrolled participants with
CKD due to diabetes and to causes other than diabetes. The
mean eGFR of participants in the DAPA-CKD trial was
13.1mL/min/1.73m2 lower than in CREDENCE, similar to that
in the Finerenone in Reducing Kidney Failure and Disease
Progression in DKD (FIDELIO-DKD) trial and the Study Of di-
abetic Nephropathy with AtRasentan (SONAR).
Conclusions. Participants with a wide range of underlying kid-
ney diseases receiving renin–angiotensin system blocking ther-
apy have been enrolled in the DAPA-CKD trial. The trial will
examine the efficacy and safety of dapagliflozin in participants
with CKD Stages 2–4 and increased albuminuria, with and
without T2D.
Keywords: chronic kidney disease, dapagliflozin, randomized
controlled clinical trial, sodium–glucose co-transporter-2
inhibitor
INTRODUCTION
In large clinical trials recruiting participants with type 2 diabe-
tes (T2D), sodium–glucose co-transporter 2 (SGLT2) inhibitors
have demonstrated beneficial effects on cardiovascular
(CV) and kidney outcomes that extend beyond glycaemic con-
trol [1–4]. One of these trials, and the first dedicated renal
trial—the Canagliflozin and Renal Events in Diabetes with
Established Nephropathy Clinical Evaluation (CREDENCE)—
involved participants with T2D and chronic kidney disease
(CKD). CREDENCE recruited individuals with an estimated
glomerular filtration rate (eGFR) of 30–<90mL/min/1.73m2
and a urinary albumin:creatinine ratio (UACR) >300–5000
mg/g]. It demonstrated that the benefits of SGLT2 inhibitors on
clinical outcomes extended to participants with T2D and CKD
who were already receiving an angiotensin-converting enzyme
inhibitor (ACEi) or an angiotensin receptor blocker (ARB) as
background renoprotective therapy [4].
An acute reduction in eGFR along with a reduction in albu-
minuria is observed on commencing SGLT2 inhibitors, even in
participants with good glycaemic control [5]. This, in conjunc-
tion with strong experimental data [6], has led to speculation
that the renoprotective effects of SGLT2 inhibitors may involve
not only improvements in metabolic parameters, but also
favourable changes to glomerular haemodynamics [7–9]. Thus,
like ACEi and ARBs [10–12], SGLT2 inhibitors may also be
beneficial to patients with non-diabetic kidney disease (DKD).
The Dapagliflozin and Prevention of Adverse outcomes in
CKD (DAPA-CKD) trial tested the hypothesis that compared
with placebo, the SGLT2 inhibitor dapagliflozin is superior in
reducing the risk of kidney and CV events in a broad group of
participants with CKD, the vast majority of whom are already
KEY LEARNING POINTS
What is already known about this subject?
• In large cardiovascular (CV) outcome trials of patients
with type 2 diabetes (T2D), sodium–glucose co-trans-
porter 2 (SGLT2) inhibitors have demonstrated benefi-
cial effects on CV outcomes.
• The Canagliflozin and Renal Events in Diabetes with
Established Nephropathy Clinical Evaluation demon-
strated that the SGLT2 inhibitor canagliflozin reduced
the risk of kidney failure and CV outcomes in patients
with T2D and chronic kidney disease (CKD; estimated
glomerular filtration rate 30–<90mL/min/1.73m2; uri-
nary albumin:creatinine ratio >300–5000mg/g) who
were already receiving an angiotensin-converting en-
zyme inhibitor (ACEi) or an angiotensin receptor
blocker (ARB).
• The kidney protective effects of SGLT2 inhibitors may
involve not only improvements in metabolic parame-
ters, but also favourable changes to glomerular haemo-
dynamics, and so SGLT2 inhibitors may also be
beneficial to patients with non-diabetic kidney disease.
What this study adds?
• The Dapagliflozin and Prevention of Adverse out-
comes in CKD (DAPA-CKD) trial tested the hypothe-
sis that compared with placebo, the SGLT2 inhibitor
dapagliflozin is superior in reducing the risk of kidney
and CV events in a broad group of patients with CKD,
the vast majority of whom are already receiving ACEis/
ARBs.
• The DAPA-CKD trial has enrolled a group of partici-
pants with a variety of kidney diseases and will allow
assessment of SGLT2 inhibition in a broad cohort of
patients with proteinuric CKD.
What impact this may have on practice or policy?
• In the context of other trials in this field, the DAPA-
CKD trial will provide unique insights into whether
dapagliflozin confers kidney protection in patients
with CKD and diverse kidney disease aetiologies.
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receiving ACEis/ARBs. Unlike CREDENCE, the DAPA-CKD
trial included participants with CKD but without T2D, to ex-
plore whether the benefits of SGLT2 inhibitors extend to
patients with non-DKD [13]. Here we describe the baseline
characteristics of participants enrolled in the DAPA-CKD trial
and compare these with characteristics of participants included
in other recent trials involving participants with T2D and/or
CKD from other causes reporting kidney outcomes as primary
endpoints.
MATERIALS AND METHODS
Study design
The DAPA-CKD trial (NCT03036150) is a randomized,
double-blind, parallel group, placebo-controlled trial that en-
rolled patients with CKD to evaluate the effects of dapagliflozin
10mg once daily compared with placebo in patients receiving
standard care, including either recommended doses or, if not,
an individual maximum tolerated dose below the maximum
recommended dose of an ACEi/ARB. The study design for the
DAPA-CKD trial has been published [13].
Participants
Eligible participants had CKD with an eGFR25–75mL/
min/1.73m2 and a UACR 200–5000mg/g (22.6–565mg/
mmol). Participants meeting these criteria could be enrolled
whether or not their kidney disease was thought to be due to
T2D. Participants with type 1 diabetes (T1D), autosomal domi-
nant or recessive polycystic kidney disease, lupus nephritis or
anti-neutrophilic cytoplasmic autoantibody-associated vasculi-
tis were excluded. Participants who had received cytotoxic or
immunosuppressive therapy for primary or secondary kidney
disease in the 6months prior to study enrolment, had a history
of organ (including kidney) transplantation and were receiving
therapy with an SGLT2 inhibitor within 8weeks prior to enrol-
ment were also excluded [13]. Randomization was capped so
that a minimum of 30% of participants were assigned to either
the diabetic or non-diabetic subgroups. Capping was also used
to limit the proportion of participants with an eGFR 60–75mL/
min/1.73m2 to<10%. Participants were maintained on a stable
and individualized maximum tolerated dose of an ACEi or
ARB for at least 4weeks before screening, if not contraindi-
cated. Participants with documented ACEi or ARB intolerance
were allowed to participate in the study. Investigators were
strongly encouraged to provide concordant care for all other
health conditions in accordance with clinical practice
guidelines.
Procedures
After randomization, face-to-face visits were scheduled after
2weeks, at 2, 4 and 8months and thereafter at 4-month inter-
vals. At each follow-up visit, data about achieving endpoints,
occurrence of adverse events, use of concomitant therapies and
adherence to trial drug were collected. Additionally, vital signs
were recorded and blood and urine were collected for labora-
tory analysis as previously described [13]. The statistical
assumptions and approach to analysis has been described previ-
ously [13].
Outcomes
The primary composite endpoint of the DAPA-CKD trial is
the worsening of kidney function, defined as sustained 50%
decline in eGFR, occurrence of end-stage kidney disease or
death due to kidney disease, or a CV death. Secondary and ex-
ploratory endpoints have been previously described [13].
Comparator trials
DKD studies. We compared the baseline characteristics of
participants with T2D enrolled in the DAPA-CKD trial with
those of participants enrolled in other contemporary Phase 3
trials enrolling patients with DKD and which assessed kidney
outcomes as the primary endpoint. We identified three such
studies: CREDENCE [4], the Finerenone in Reducing Kidney
Failure and Disease Progression in DKD (FIDELIO-DKD) trial
[14] and the Study Of diabetic Nephropathy with AtRasentan
(SONAR) [15]. We also identified two other ongoing kidney
outcomes studies—Study of Heart and Kidney Protection With
Empagliflozin (EMPA-KIDNEY; NCT03594110) [16] and the
research study to see how semaglutide works compared with
placebo in people with T2D and CKD (FLOW; NCT03819153)
[17]—recruiting participants with T2D (participants with T1D
are included in the EMPA-KIDNEY study) and CKD, for which
baseline characteristics of the participants have not yet been
published. For these studies, participants were compared with
those recruited into the DAPA-CKD trial based on the eligibil-
ity criteria (Table 1).
Non-DKD trials. To compare the number of non-diabetic
participants randomized in the DAPA-CKD trial to other rele-
vant studies, we searched for Phase 3 randomized trials using
therapeutic interventions in participants with non-DKDs
reporting kidney outcomes as the primary endpoint. We found
two completed trials that had recruited patients with immuno-
globulin A (IgA) nephropathy (IgAN). The Therapeutic
Evaluation of Steroids in IgAN Global trial (TESTING) [18]
and the Supportive Versus Immunosuppressive Therapy for the
Treatment of Progressive IgAN (STOP-IgAN) trial [19] both
tested conventional immunosuppressive regimens against con-
tinued supportive care. Two ongoing trials examining the pro-
gression of CKD in participants with IgAN—A Study of the
Effect and Safety of Sparsentan in the Treatment of Patients
With IgAN (PROTECT) [20] and the Efficacy and Safety of
Nefecon in Patients With Primary IgAN (NefIgArd) study
[21]—were also identified.
RESULTS
Recruitment
The first participant was enrolled on 2 February 2017 and
the first randomization occurred on 13 February 2017.
Recruitment closed in the majority of participating countries on
6 July 2018. Recruitment in India, the USA and Canada was
open until 19 October 2018, recruiting 4094 participants for
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randomization. Recruitment in China opened on 2 December
2019 and was ongoing until the trial end date of 3 April 2020,
recruiting 210 participants from this country. Overall, 4304
were enrolled in the trial.
Patient characteristics
The mean age of the participants in the DAPA-CKD trial
was 61.8 years and 66.9% were men (Table 2). There was a mix
of races in the participants, with 53.2%White, 34.1% Asian and
4.4% Black. The mean systolic/diastolic blood pressure was
137/78mmHg. The overall mean body mass index (BMI) was
29.5 kg/m2 and the mean haemoglobin A1c (HbA1c) was 7.1%
(54mmol/mol). Overall, the mean eGFR was 43.1mL/min/
1.73m2. Among the 4304 participants enrolled, 624 (14.5%),
1898 (44.1%), 1328 (30.9%) and 454 (10.5%) had an eGFR<30,
30–<45, 45–<60 and 60 mL/min/1.73m2, respectively.
The median UACR was 949.3mg/g (107.3mg/mmol) with 1
(0.0%), 444 (10.3%) and 3859 (89.7%) participants having a
UACR <30, 30–300 and >300mg/g (<3.39, 3.39–33.9,
>33.9mg/mmol), respectively (Table 2). The proportion of
participants in the eGFR categories <30, 30–<45, 45–<60
and 60mL/min/1.73m2 and UACR categories 300, >300–
1000,>1000–3000 and>3000mg/g are shown in Figure 1.
Of the 4304 randomized participants, 2888 had a history
of T2D at the start of the trial. Of the participants with no
history of diabetes, 19 had HbA1c 6.5% (48mmol/mol) at
Visit 1 (enrolment) and 2 (randomization) and thus fulfilled
criteria for a diagnosis of diabetes. Therefore 2906 partici-
pants (67.5%) had a diagnosis of diabetes at baseline and
were included in the diabetes subgroup in subsequent analy-
ses (Figure 2a).
Causes of CKD
In participants without T2D, the most common
investigator-reported cause of CKD was chronic glomerulone-
phritis (n¼ 598), followed by ischaemic/hypertensive nephrop-
athy (n¼ 487) (Table 3 and Figure 2B). The cause of CKD was
considered ‘unknown’ in 167 participants without diabetes. In
396 participants in the diabetic population, CKD was not
attributed to diabetic nephropathy by the investigator
(Figure 2C). The cause of CKD was based on kidney biopsy in
373 (12.8%) of the participants with T2D and 500 (35.8%) of
the participants without T2D.
Concomitant diseases
Overall, a history of CV disease was recorded in 37.4% of
participants, 10.9% had a history of heart failure, 9.1% had a
history of myocardial infarction and 6.9% had a history of
stroke (Table 3). Among patients with T2D, the mean time
since diabetes was confirmed was 15 years and 44.1% had a his-
tory of CV disease. A history of heart failure was recorded for
12.4%, myocardial infarction for 11.0% and stroke for 7.9% of
participants (Table 3).
Blood pressure, renoprotective and lipid-lowering
medications
Although the intention was to recruit patients taking the
maximum target dose or, if not, at individually maximum toler-
ated dose of ACEi or ARB, patients could still be included if
intolerant of these drugs. In the overall study population,
130 participants (3.0%) were not taking either medication at the
baseline visit (Visit 2). More participants were being treated
with ARBs (66.7%) than ACEis (31.5%; Table 4), while 229
(5.3%) were taking a mineralocorticoid receptor antagonist
(MRA) and 3 participants (0.1%) were receiving a direct renin
inhibitor. After ACEi/ARBs, calcium channel blockers were the
most commonly prescribed blood pressure medication (50.7%),
followed by diuretics (43.7%) and beta-blockers (39.0%). Statins
were prescribed for 64.9% participants at baseline in the overall
study population, with a higher proportion of participants with
T2D (71.6%) receiving this class of medication than those with-
out diabetes (50.9%).
Medications for treatment of diabetes
Almost all participants with T2D (93.16%) were receiving
glucose-lowering medications, with more than half (55.0%) re-
ceiving insulin (Table 4). Of the oral glucose-lowering agents,
biguanides predominated (42.8%), followed by sulphonylureas
(26.6%) and dipeptidyl peptidase-4 inhibitors (25.5%). Only
Table 1. Comparison of eligibility criteria for the DAPA-CKD trial and other contemporary Phase 3 trials recruiting participants with CKD and T2D
(from clinicaltrials.gov)
Parameter DAPA-CKD EMPA-KIDNEY FLOW
Study drug Dapagliflozin Empagliflozin Semaglutide
Comparator Placebo Placebo Placebo
Recruitment 4000 6000 3160
Non-diabetic CKD included Yes Yes No
T1D Excluded Included Excluded
Background ACEi/ARB Unless not tolerated Unless not tolerated or not indicated Unless not tolerated or
contraindicated
Age (years) 18 18 18 (Japan 20)
eGFR range 25–75mL/min/1.73m2 20–90mL/min/1.73m2 25–75mL/min/1.73m2
UACR range 200mg/g to 5000mg/g 200mg/g if eGFR 45 to
<90mL/min/1.73m2
300–5000mg/g,
100mg/g if eGFR
50mL/min/1.73m2
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4.2% of participants with T2D were receiving a glucagon-like
peptide-1 receptor agonist (GLP1-RA) and 3.4% were receiv-
ing thiazolidinediones.
Comparisons of participants with and without T2D
Participants with T2D tended to be older than those with-
out diabetes (mean age 64 versus 56 years) and the proportion
65 years was greater (48% versus 30%), but both subgroups
had a similar racial distribution (Table 2). Patients with diabe-
tes had a higher BMI than those without diabetes (mean BMI
30.3 versus 27.9 kg/m2), were more likely to be hypertensive
(98.3% versus 90.5%) and were more likely to be anaemic
whether male (32.9% versus 19.7%) or female (18.1% versus
12.9%). The mean HbA1c in patients with and without diabe-
tes was 7.8% (62mmol/mol) and 5.6% (38mmol/mol), re-
spectively. Those with T2D had a slightly higher mean eGFR
compared with those without diabetes (43.8 versus 41.7mL/
min/1.73m2) and a higher median level of albuminuria
[1016.5mg/g versus 861.0mg/g (114.9mg/mmol versus
Table 2. DAPA-CKD trial participant demographics and baseline clinical chemistry according to baseline diabetes status (full analysis set)
Characteristic Overall With T2D Without T2D
(N¼ 4304) (n¼ 2906) (n¼ 1398)
Age (years), mean (SD) 61.8 (12.1) 64.4 (9.7) 56.4 (14.6)
65 years, n (%) 2486 (57.8) 1507 (51.9) 979 (70.0)
>65 years, n (%) 1818 (42.2) 1399 (48.1) 419 (30.0)
Gender, n (%)
Male 2879 (66.9) 1941 (66.8) 938 (67.1)
Female 1425 (33.1) 965 (33.2) 460 (32.9)
Race, n (%)
White 2290 (53.2) 1541 (53.0) 749 (53.6)
Black 191 (4.4) 137 (4.7) 54 (3.9)
Asian 1467 (34.1) 932 (32.1) 535 (38.3)
American Indian/Alaska native 136 (3.2) 111 (3.8) 25 (1.8)
Other 220 (5.1) 185 (6.4) 35 (2.5)
Region, n (%)
Asia 1346 (31.3) 841 (28.9) 505 (36.1)
Europe 1233 (28.7) 771 (26.5) 462 (33.0)
North America 813 (18.9) 623 (21.4) 190 (13.6)
Latin/South America 912 (21.2) 671 (23.1) 241 (17.2)
Blood pressure (mmHg), mean (SD)
Systolic 137.1 (17.4) 139.2 (17.3) 132.6 (16.7)
Diastolic 77.5 (10.5) 76.5 (10.1) 79.6 (10.9)
Systolic blood pressure categories, n (%)
>130mmHg 2762 (64.2) 2033 (70.0) 729 (52.1)
>140mmHg 1684 (39.1) 1273 (43.8) 411 (29.4)
Mean BMI (kg/m2) n¼ 4296 n¼ 2899 n¼ 1397
29.5 30.3 27.9
HbA1c n¼ 4284 n¼ 2893 n¼ 1391
%, mean (SD) 7.1 (1.7) 7.8 (1.7) 5.6 (0.4)
mmol/mol, mean (SD) 54 (19) 62 (19) 38 (4)
Haemoglobin (g/L), mean (SD) n¼ 4278 n¼ 2892 n¼ 1386
128.3 (18.1) 125.9 (17.9) 133.1 (17.6)
Serum creatinine (mg/dL), mean (SD) 1.7 (0.5) 1.6 (0.5) 1.8 (0.5)
eGFR (mL/min/1.73m2), mean (SD) 43.1 (12.4) 43.8 (12.6) 41.7 (11.7)
eGFR categories(mL/min/1.73m2), n (%)
60 454 (10.5) 348 (12.0) 106 (7.6)
45–59 1328 (30.9) 918 (31.6) 410 (29.3)
30–44 1898 (44.1) 1239 (42.6) 659 (47.1)
<30 624 (14.5) 401 (13.8) 223 (16.0)
Baseline UACR (mg/g), median 949.3 1016.5 861.0
Baseline median UACR categories, n (%)
<30mg/g (Stage A1) 1 (0.0) 1 (0.0) 0 (0.0)
30–300mg/g (Stage A2) 444 (10.3) 308 (10.6) 136 (9.7)
>300mg/g (Stage A3) 3859 (89.7) 2597 (89.4) 1262 (90.3)
<30 ≥30 to <45 ≥45 to <60 ≥60
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FIGURE 1: Proportion of participants in the eGFR and UACR
categories.
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97.3mg/mmol)]. Participants with T2D were more than twice as
likely to have had a prior myocardial infarction (11.0% versus
5.1%) or history of heart failure (12.4 versus 7.7%; Table 3).
Comparison of the baseline characteristics of study
participants of the DAPA-CKD trial with those of par-
ticipants recruited into other contemporary diabetic ne-
phropathy and other CKD trials
One other trial, CREDENCE [4], assessed the clinical bene-
fits and safety of an SGLT2 inhibitor in patients with T2D and
CKD on a background of ACEi/ARB therapy; however, patients
with non-DKD were not enrolled in this study (Table 5). The
DAPA-CKD trial participants with diabetes were racially more
diverse and had a lower BMI compared with those enrolled in
CREDENCE. The mean eGFR of the overall population of
patients recruited to the DAPA-CKD trial was 13.1mL/min/
1.73m2 lower than in CREDENCE (43.1 versus 56.2mL/min/
1.73m2, respectively). Overall, the UACR was similar to that in
CREDENCE [949 (107) versus 927mg/g (105mg/mmol)] de-
spite the lower level for inclusion in the DAPA-CKD trial
(200mg/g) compared with CREDENCE (300mg/g).
Comparing the populations with T2D, the median UACR value
67.5%  With Type 2 diabetes
32.5%  Without Type 2 diabetes
58.3%  Diabetic Nephropathy
16.0%  Ischaemic/Hypertensive Nephropathy
  6.3%  IgA Nephropathy
  2.7%  Focal Segmental Glomerulosclerosis
  1.6%  Chronic Pyelonephritis
  1.2%  Chronic Interstitial Nephritis
  5.0%  Unknown Cause
  8.9%  Other
86.4%  Diabetic Nephropathy
  6.9%  Ischaemic/Hypertensive Nephropathy
  3.3%  Glomerulonephritis
  3.4%  Other
A
B
C
FIGURE 2: Characteristics of study participants: (A) study participants by diabetes status, (B) investigator-reported causes of CKD in all study
participants and (C) investigator-reported causes of CKD in study participants with T2D.
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for DAPA-CKD [1017mg/g (115mg/mmol)] was similar to
that for CREDENCE [927mg/g (105mg/mmol)]. The UACR
in the DAPA-CKD, FIDELIO-DKD and SONAR studies was
similar (949 versus 851 and 802 mg/g [107 versus 96 and
91mg/mmol]) [14, 15]. The mean eGFR of the DAPA-CKD
trial participants with T2D (43.8mL/min/1.73m2) was similar
to that reported for two other completed trials, FIDELIO-DKD
(44.3mL/min/1.73m2) [14] and SONAR (43.8mL/min/
1.73m2) [15].
Unlike CREDENCE, patients intolerant of ACEi/ARB
were eligible for the DAPA-CKD trial, although only 3% of
participants were not recorded as receiving these medications
at the time of recruitment as compared 0.1% in CREDENCE
[4]. This requirement for the use of prior renin–angiotensin
system (RAS) blockade agents was also applied in the
FIDELIO-DKD trial (99.9%) [14], but was less stringent in
the SONAR trial [15], with 2% of patients not receiving these
agents at baseline [22]. Compared with these other studies, a
similar proportion of participants with diabetes recruited
into the DAPA-CKD trial were prescribed statins (72% in
DAPA-CKD versus 69% in CREDENCE, 74% in FIDELIO-
DKD and 78% in SONAR) and GLP1-RA (4.2% in DAPA-
CKD and CREDENCE, 7.0% in FIDELO-DKD). Finally, the
FLOW study of semaglutide [17] is recruiting participants
with T2D with an eGFR range similar to that of the DAPA-
CKD trial.
After DKD, chronic glomerulonephritis was the most com-
mon diagnosis of kidney disease in the DAPA-CKD trial, of
which the largest group of participants had a diagnosis of IgAN.
Figure 3 shows that the size of the IgAN cohort in the DAPA-
CKD trial was larger than that of other recently completed
IgAN trials.
DISCUSSION
The DAPA-CKD trial has enrolled participants with albumin-
uria and a wide range of kidney diseases, the majority already
receiving RAS blockade therapy. It is one of three large outcome
trials (with CREDENCE and EMPA-KIDNEY) assessing the
effects of SGLT2 inhibitors on the progression of CKD with
kidney endpoints as the primary outcome. Notably, the study
was stopped early following routine review by the Independent
Data Monitoring Committee, who cited overwhelming
efficacy [23].
Unlike CREDENCE, the only SGLT2 inhibitor trial to have
reported results to date [4], the DAPA-CKD trial recruited
patients with CKD both with and without T2D and will be the
first SGLT2 inhibitor trial to report clinical outcome data in
Table 3. CKD diagnosis and other baseline comorbidities according to baseline diabetes status (full analysis set)
Baseline comorbidities Overall
(N¼ 4304)
With T2D
(n¼ 2906)
Without T2D
(n¼ 1398)
Investigator reported aetiology of CKD
Diabetic nephropathy 2510 (58.3) 2510 (86.4) 0
Ischaemic/hypertensive nephropathy 687 (16.0) 200 (6.9) 487 (34.8)
Chronic glomerulonephritis 695 (16.1) 97 (3.3) 598 (42.8)
IgAN 270 (6.3) 38 (1.3) 232 (16.6)
FSGS 115 (2.7) 22 (0.8) 93 (6.7)
Membranous nephropathy 43 (1.0) 10 (0.3) 33 (2.4)
Minimal change disease 11 (0.3) 2 (0.1) 9 (0.6)
Other 256 (5.9) 25 (0.9) 231 (16.5)
Chronic pyelonephritis (infectious) 69 (1.6) 12 (0.4) 57 (4.1)
Chronic interstitial nephritis 53 (1.2) 13 (0.4) 40 (2.9)
Obstructive nephropathy 25 (0.6) 5 (0.2) 20 (1.4)
Renal artery stenosis 10 (0.2) 3 (0.1) 7 (0.5)
Unknown 214 (5.0) 47 (1.6) 167 (11.9)
Other 41 (1.0) 19 (0.7) 22 (1.6)
Kidney biopsy performed 873 (20.3) 373 (12.8) 500 (35.8)
Medical history and comorbidities
Obese (BMI 30 kg/m2) 1917 (44.5) 1437 (49.4) 480 (34.3)
Hypertension 4121 (95.7) 2856 (98.3) 1265 (90.5)
Duration of diabetes (years), mean N/A 15.0 N/A
Any history of CV disease 1610 (37.4) 1281 (44.1) 329 (23.5)
Heart failure 468 (10.9) 361 (12.4) 107 (7.7)
Myocardial infarction 392 (9.1) 321 (11.0) 71 (5.1)
Percutaneous coronary intervention 294 (6.8) 246 (8.5) 48 (3.4)
Coronary artery bypass graft 176 (4.1) 163 (5.6) 13 (0.9)
Stroke 298 (6.9) 230 (7.9) 68 (4.9)
Foot ulcer 152 (3.5) 151 (5.2) 1 (0.1)
Amputation 181 (4.2) 166 (5.7) 15 (1.1)
Neuropathy 955 (22.2) 922 (31.7) 33 (2.4)
Anaemia
Men 1231 (28.6) 955 (32.9) 276 (19.7)
Women 708 (6.4) 527 (18.1) 181 (12.9)
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non-diabetic CKD patients. Inclusion of non-diabetic patients
with CKD will help to determine whether the renoprotective
effects of SGLT2 inhibitors demonstrated in CREDENCE [4]
also extend to these individuals. Of the 2906 patients with T2D
included, the mean duration of diabetes is broadly similar to
other DKD studies, reflecting the fact that patients generally de-
velop kidney disease several years after the diagnosis of T2D.
All but 3% of participants were receiving ACEi/ARB at the time
of enrolment.
The DAPA-CKD trial recruited participants with a mean
baseline eGFR of 43.1mL/min/1.73m2, 13.1mL/min/1.73m2
lower than in CREDENCE, allowing assessment of renoprotec-
tion in a group of patients with more severely impaired kidney
function than previously studied. The DAPA-CKD trial also in-
cluded 624 patients (14.5%) with a baseline eGFR <30mL/
min/1.73m2. Although such participants were theoretically ex-
cluded from CREDENCE on the basis of blood results at
screening visits, 174 (4%) CREDENCE participants had an
eGFR 30mL/min/1.73m2 on the day of randomization (G.
Bakris, submitted for publication). The only kidney outcome
trial in participants with T2D and CKD to have recruited
patients with a lower mean eGFR than DAPA-CKD
was Reduction of End Points in Non-Insulin-Dependent
Diabetes With the Angiotensin II Antagonist Losartan
(RENAAL) (41mL/min/1.73m2) [24]. In comparison, the
mean eGFR values of the SONAR (43.8mL/min/1.73m2) [15,
22] and FIDELIO-DKD (44.3mL/min/1.73m2) [14] popula-
tions are similar to the DAPA-CKD trial. These differences are
likely to reflect the eGFR inclusion criteria for these trials, with
CREDENCE having an upper cut-off of 90mL/min/1.73m2
[25] as compared with 75mL/min/1.73m2 for the DAPA-CKD,
FIDELIO-DKD and SONAR [13–15] trials. In addition, the
lower eGFR cut-off for CREDENCE was higher, at 30mL/min/
1.73m2, than for the DAPA-CKD, SONAR and FIDELIO-
DKD trials (25mL/min/1.73m2). Despite the inclusion criteria
of the DAPA-CKD trial allowing recruitment of patients with a
lower UACR than CREDENCE [200mg/g (22.6mg/mmol)
compared with 300mg/g (33.9mg/mmol)], the median UACR
values in the DAPA-CKD diabetic population were higher than
in CREDENCE.
Even among patients with T2D, other causes of CKD are
often identifiable. Of the 2906 participants with diabetes
recruited into the DAPA-CKD trial, 2510 (86%) had been
given a diagnosis of ‘diabetic nephropathy’ at baseline by the
investigator, with 396 diagnosed with an alternative kidney
disease. Among all participants with diabetes, 373 had under-
gone a kidney biopsy. These data are consistent with prior
observational studies indicating that a high proportion of
Table 4. Baseline medications according to baseline diabetes status (full analysis set)
Baseline medication Overall
(N¼ 4304)
With T2D
(n¼ 2906)
Without T2D
(n¼ 1398)
RAS blockade 4174 (97.0) 2817 (96.9) 1357 (97.1)
ACEi 1354 (31.5) 894 (30.8) 460 (32.9)
ARB 2870 (66.7) 1958 (67.4) 912 (65.2)
Direct renin inhibitor 3 (0.1) 0 3 (0.2)
ARNI 3 (0.1) 3 (0.1) 0
Diuretic medication 1882 (43.7) 1465 (50.4) 417 (29.8)
Loop diuretic 1056 (24.5) 841 (28.9) 215 (15.4)
Thiazide 906 (21.1) 715 (24.6) 191 (13.7)
MRA 229 (5.3) 171 (5.9) 58 (4.1)
Other diuretic 27 (0.6) 18 (0.6) 9 (0.6)
Phosphate binder 48 (1.1) 39 (1.3) 9 (0.6)
ESA 89 (2.1) 68 (2.3) 21 (1.5)
Potassium binder 117 (2.7) 88 (3.0) 29 (2.1)
Beta-blocking agent 1680 (39.0) 1267 (43.6) 413 (29.5)
Calcium channel blocker 2183 (50.7) 1549 (53.3) 634 (45.4)
Lipid-lowering medication 2988 (69.4) 2206 (75.9) 782 (55.9)
Statin 2794 (64.9) 2082 (71.6) 712 (50.9)
Other lipid-lowering medication 645 (15.0) 452 (15.6) 193 (13.8)
Antithrombotic medication 2042 (47.4) 1649 (56.7) 393 (28.1)
Antiplatelet agent 1880 (43.7) 1543 (53.1) 337 (24.1)
Other antithrombotic medication 225 (5.2) 158 (5.4) 67 (4.8)
Antihyperglycaemic medication 2725 (63.3) 2719 (93.6) 6 (0.4)
Biguanide 1250 (29.0) 1244 (42.8) 6 (0.4)
Sulphonylurea 774 (18.0) 774 (26.6) 0
DPP-4 inhibitor 742 (17.2) 742 (25.5) 0
Alpha-glucosidase inhibitor 99 (2.3) 99 (3.4) 0
GLP-1 receptor agonist 122 (2.8) 122 (4.2) 0
Insulin 1598 (37.1) 1598 (55.0) 0
Thiazolidinedione 91 (2.1) 91 (3.1) 0
Other antihyperglycaemic medication 89 (2.1) 89 (3.1) 0
Values presented as n (%).
ARNI, angiotensin receptor-neprilysin inhibitor; DPP-4, dipeptidyl peptidase-4; ESA, erythropoiesis-stimulating agents.
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participants with T2D and CKD have kidney pathologies
other than DKD when systematically subjected to kidney bi-
opsy [26]. It seems highly likely that other studies enrolling
participants with T2D and CKD, including CREDENCE, have
recruited participants with non-DKD because histological
diagnosis based on prior kidney biopsy has not been an inclu-
sion criterion. Because these participants have not been
clearly identified in prior studies, subgroup analysis assessing
the impact of interventions on progression of non-DKD has
not been possible.
Table 5. Comparison of the DAPA-CKD diabetic subpopulation with populations recruited to other contemporary trials of DKD in patients already re-
ceiving RAS blockade
Characteristic DAPA-CKD CREDENCE [4] FIDELIO-DKD [14] SONAR [31]
Patients with CKD and diabetes 2906 4401 5674 2648a
Patients with DKD, % 86.4 100 100 100
Other aetiology, % 13.6 0 0 0
Study drug Dapagliflozin Canagliflozin Finerenone Atrasentan
Age (years), mean 64.4 63.0 65.6 64.8
Gender, %
Male 66.8 66.1 70.2 74.2
Female 33.2 33.9 29.8 25.8
Race, %
White 53.0 66.6 65.9 56.5
Black 4.7 5.1 4.7 5.6
Asian 32.1 19.9 25.3 34.0
Other 10.2 8.4 3.8 3.8
Duration of diabetes (years), mean (SD) Median 15.0 15.8 (8.6) 16.6 (8.8) 16.7 (9.1)
History of CV disease, % 44.1 50.4 45.9 –
History of heart failure, % 12.4 14.8 7.5 –
History of myocardial infarction, % 11.0 – 13.5 6.0
History of stroke, % 7.9 – 12.1 –
Blood pressure (mmHg), mean (SD)
Systolic 139 (17) 140 (16) 138 (14) 136 (15)
Diastolic 77 (10) 78 (9) 76 (10) 75 (10)
BMI (kg/m2), mean (SD) Median 29.0 31.3 (6.2) 31.1 (6.0) –
HbA1c (%), mean (SD) 7.8 (1.7) 8.3 (1.3) 7.7 (1.3) 7.8 (1.5)
HbA1c (mmol/mol), mean (SD) 62 (19) 67 (14) 61 (14) 62 (16)
eGFR, (mL/min/1.73m2), mean (SD) 43.8 (12.6) 56.2 (18.2) 44.3 (12.6) 43.8 (13.7)
eGFR categories (mL/min/1.73 m2), %
60 12.0 40.2 11.6 –
45–<60 31.6 28.8 33.5 –
30–<45 42.6 27.1 52.5b –
<30 13.8 3.9 – –
<25 – – 2.4
UACR (mg/g), median (25–75 percentile) 1017 927 (463–1833) 851 (446–1634) 802 (450–1469)
UACR categories (mg/g), %
<30 0 0.7c 0.4 –
30–300 10.6 11.3c 12.1d –
>300 89.4 88.0c 87.4d –
Antihyperglycaemic medications, %
Biguanide 42.8 57.8 43.8 38.1
Sulphonylurea 26.6 28.8 23.4 28.4
DPP-4 inhibitor 25.5 17.1 26.8 –
Alpha-glucosidase inhibitor 3.4 – – –
GLP-1 receptor agonist 4.2 4.2 7.0 –
Insulin 55.0 65.5 64.1 62.5
Thiazolidinedione 3.1 – – –
CV medications, %
RAS blockade 96.9 99.9e 99.9 98.0
Diuretic 50.4 46.7 56.6 82.6
Antithrombotic 56.7 59.6 56.8 –
Beta-blocker 43.6 40.2 52.2 41.7
Statin 71.6 69.0 74.3 78.4
Calcium channel blocker 53.3 – 63.2 57.6
aNumber of participants who were classed as ‘responders’ and enrolled into UACR responder stratum of the study.
beGFR range 25–<45mL/min/1.73m2.
cNormoalbuminuria/microalbuminuria/macroalbuminuria.
d<30/30–<300/300mg/g.
eRenin–angiotensin–aldosterone system blockade.
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Taking the DAPA-CKD trial participants overall, the most
common non-diabetic cause of CKD was ‘chronic glomerulo-
nephritis’ (predominantly IgAN) followed by ‘ischaemic/hyper-
tensive nephropathy’. In total, there were 270 participants
with a diagnosis of IgAN, including 38 participants with
diabetes, making the DAPA-CKD trial one of the largest trials
to date involving participants with confirmed IgAN (Figure 3).
Larger recruitment targets are proposed for forthcoming
trials in IgAN, including the PROTECT [27] and NefigArd
studies [21].
The second-largest non-diabetic nephropathy group were
participants reported to have had hypertensive/ischaemic ne-
phropathy, a diagnosis often made without kidney biopsy. A
further 115 participants had a diagnosis of focal segmental glo-
merulosclerosis (FSGS), more than the number studied in the
randomized, double-blind, active-control, dose-escalation
(DUET) Phase 2 trial, which compared the effect of the dual
endothelin type A and angiotensin 2 type 1 receptor antagonist
sparsentan versus irbesartan on albuminuria in patients with a
diagnosis of primary FSGS [28]. The ongoing Phase 3 DUPLEX
trial has been designed to assess the impact of sparsentan on
eGFR slope and proteinuria in 300 participants with biopsy-
proven FSGS [29].
As expected in participants with proteinuric CKD, many of
the DAPA-CKD participants had a prior history of CV diseases,
including heart failure. Participants with T2D were about twice
as likely to have had a prior history of coronary artery disease,
including myocardial infarction, percutaneous coronary inter-
vention and coronary artery bypass, than those with CKD but
without diabetes. A similar pattern was seen with heart failure
(12.4% of participants with T2D but only 7.7% of participants
without diabetes). The higher prevalence of both atherosclerotic
CV disease and heart failure in the diabetic population is
important, as it may impact treatment effects and result in a dif-
ferentiated secondary outcome between the diabetic and non-
diabetic population in the DAPA-CKD trial.
More than 50% of the diabetic cohort were receiving insulin,
reflecting the long duration of diabetes in many of these partici-
pants. Biguanides were the most commonly prescribed oral
hypoglycaemic agents, bearing in mind that only 15% of the di-
abetic subgroup had an eGFR<30mL/min/1.73m2 (the level at
which most guidelines preclude the prescription of metformin
due to the enhanced risk of lactic acidosis) [30].
Two other classes of drug, namely MRAs and GLP1-RA, are
of particular interest because their impact on kidney outcomes
is currently being assessed in clinical trials in patients with dia-
betes and CKD. The FIDELIO-DKD trial is assessing the clini-
cal efficacy and safety of finerenone on kidney outcomes in a
similar cohort of participants with diabetes and kidney disease
(Table 5). According to a recent press release, the FIDELIO-
DKD study met its primary and secondary endpoints [32]. The
FLOW trial is examining the efficacy and safety of semaglutide,
a GLP1-RA, added to an ACEi/ARB in a similar population
(Table 1). With 5.9% of the population with diabetes in the
DAPA-CKD trial prescribed MRAs and 4.2% GLP1-RAs, the
study will be limited in providing a robust assessment of the ef-
fect of dapagliflozin on kidney and CV endpoints when added
to these medications.
In conclusion, the DAPA-CKD trial has enrolled a group of
participants with a variety of kidney diseases and will allow as-
sessment of SGLT2 inhibition in a broad cohort of patients with
proteinuric kidney disease. While small mechanistic studies
have demonstrated that SGLT2 inhibitors exert physiological
effects in people with non-DKD, including a characteristic hae-
modynamic ‘dip’ in GFR [9], the DAPA-CKD trial is the first to
capture the effects on clinical kidney outcomes. In the context
of other trials in this field, the DAPA-CKD trial will provide
unique insights into how to treat patients with kidney disease
due to diverse aetiologies.
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